Arcus Biosciences counsel exercises 34,090 options

Arcus Biosciences General Counsel Carolyn C. Tang exercised stock options to acquire 34,090 shares of common stock at $2.574 per share on June 11, 2026.

Accepted by SEC EDGAR 06/12/2026 - 04:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arcus Biosciences General Counsel Carolyn C. Tang exercised stock options to acquire 34,090 shares of common stock at $2.574 per share on June 11, 2026. This was a derivative exercise, not an open-market purchase.

The fully vested option was completely exercised, leaving no remaining options from this grant. Following the transaction, Tang directly holds 184,607 common shares, which include 1,783 shares purchased through the company’s Employee Stock Purchase Plan and unvested RSU awards.

Insider Trade Summary

34,090 shares exercised/converted

Exercise 2 txns

Insider Tang Carolyn C.

Role General Counsel

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	34,090	$2.574	$88K
Exercise	Common Stock	34,090	$2.574	$88K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 184,607 shares (Direct)

Footnotes (3)

1. F1. Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
2. F2. Includes the unvested portion of the Reporting Person's RSU grants.
3. F3. The option is fully vested and has been completely exercised.

Key Figures

Options exercised: 34,090 shares Exercise price: $2.574 per share Shares held after: 184,607 shares +3 more

6 metrics

Options exercised 34,090 shares Stock option exercise into common stock on June 11, 2026

Exercise price $2.574 per share Strike price for 34,090 stock options exercised

Shares held after 184,607 shares Total direct common shares after transaction

ESPP shares included 1,783 shares Purchased on May 31, 2026 via Employee Stock Purchase Plan

Exercised option remaining 0 shares Fully vested option grant now completely exercised

Derivative exercises reported 1 transaction Form 4 transactionSummary exerciseCount

Key Terms

Employee Stock Purchase Plan, RSU, Stock Option (Right to Buy), derivative exercise/conversion

4 terms

Employee Stock Purchase Plan financial

"Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

RSU financial

"Includes the unvested portion of the Reporting Person's RSU grants."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcus Biosciences (RCUS) report for Carolyn C. Tang?

Arcus Biosciences reported that General Counsel Carolyn C. Tang exercised stock options to acquire 34,090 common shares at $2.574 per share. This was a derivative exercise, converting options into stock rather than an open-market share purchase.

How many Arcus Biosciences (RCUS) shares does Carolyn C. Tang hold after the Form 4 transaction?

After the June 11, 2026 transaction, Carolyn C. Tang holds 184,607 Arcus Biosciences common shares directly. This total includes shares gained from the option exercise, 1,783 shares bought via the Employee Stock Purchase Plan, and unvested RSU grants.

Was the Arcus Biosciences (RCUS) Form 4 transaction an open-market buy or option exercise?

The Form 4 shows an option exercise, not an open-market buy. Tang exercised a fully vested stock option covering 34,090 shares at a $2.574 exercise price, converting derivative rights into common stock and eliminating that option position.

What happened to Carolyn C. Tang’s stock option position in Arcus Biosciences (RCUS)?

The reported stock option was fully exercised and is now exhausted. Tang exercised rights to 34,090 underlying shares at $2.574 per share, leaving zero shares remaining under that particular option grant after the June 11, 2026 transaction.

Does the Arcus Biosciences (RCUS) Form 4 mention RSUs or ESPP shares for Carolyn C. Tang?

Yes. The filing notes that Tang’s reported holdings include 1,783 shares purchased on May 31, 2026 through the Employee Stock Purchase Plan, as well as the unvested portion of her restricted stock unit (RSU) grants in the total share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tang Carolyn C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		M		34,090	A	$2.574	184,607(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.574	06/11/2026		M			34,090	(3)	08/30/2027	Common Stock	34,090	$2.574	0	D

Explanation of Responses:

1. Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option is fully vested and has been completely exercised.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)